Research & Reviews: A Journal of Drug Formulation, Development and Production
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP
<p align="center"><a title="RRJoDFDP" href="http://stmjournals.com/Journal-of-Drug-Formulation-Development-and-Production.html" target="_blank"><strong><span>Research & Reviews: A Journal of Drug Formulation, Development and Production (RRJoDFDP)</span></strong> </a>is a Journal focused towards the publication of current Research/Review work carried out in an area of Drug Formulation, development and production. It's a triannual journal, started in 2014.</p><p align="center"><strong><span>eISSN: 2394-1944</span></strong></p><p align="center"><strong><span><strong>Scientific Journal Impact Factor (SJIF):</strong><span> </span><strong>6.071</strong></span></strong></p><p align="center"><strong><span>Journal DOI no.: 10.37591/RRJoDFDP</span></strong></p><p align="center">Indexed in: DRJI, Citefactor, Journal TOC, Google Scholar, Index Copernicus (<a href="https://journals.indexcopernicus.com/search/details?id=51539&lang=pl">ICV = 60.22</a>)</p><p align="center"><strong>Editor-In-Chief</strong></p><p align="center">Dr. Waseem Rizvi,</p><p align="center">Professor, Department of Pharmacology, Aligarh Muslim University, Aligarh, Uttar Pradesh-202001, India Email: Waseemnakhat[at]gmail[dot]com</p><p align="center"><a title="Editorial Board" href="/index.php/RRJoDFDP/about/editorialTeam" target="_blank">COMPLETE EDITORIAL BOARD</a></p><p align="center"> </p><p><strong><br /></strong></p><p><strong>Focus and Scope Covers</strong></p><ul><li>Drug Development</li><li>Novel drug delivery systems</li><li>International Drug regulatory Affair</li><li>Pharmacodynamics & pharmacokinetics</li><li>Medicinal Chemistry</li><li>Topical Formulations</li><li>Galenic formulations</li><li>Injectable formulations</li><li>Sub-micron and Nano-emulsions</li></ul><p align="center">All contributions to the journal are rigorously refereed and are selected on the basis of quality and originality of the work. The journal publishes the most significant new research papers or any other original contribution in the form of reviews and reports on new concepts in all areas pertaining to its scope and research being done in the world, thus ensuring its scientific priority and significance.</p><p align="center"><a title="Peer Review Process" href="/index.php/RRJoDFDP/about/editorialPolicies#peerReviewProcess" target="_blank">Peer Review Process</a></p><p align="center"><a title="Peer Review Process" href="/index.php/RRJoDFDP/about/editorialPolicies#peerReviewProcess" target="_blank">Author Guidelines</a></p><p><a title="Author Guidelines" href="http://stmjournals.com/pdf/Author-Guidelines-stmjournals.pdf" target="_blank"> </a></p><table style="border-collapse: collapse; width: 48pt;" width="64" border="0" cellspacing="0" cellpadding="0"><tbody><tr style="height: 15.0pt;"><td class="xl65" style="height: 15.0pt; width: 48pt;" align="right" width="64" height="20">6.071</td></tr></tbody></table>en-USResearch & Reviews: A Journal of Drug Formulation, Development and Production2394-1944<p align="center"><strong>Declaration and Copyright Transfer Form</strong></p><p align="center">(to be completed by authors)</p><p>I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is <strong>not</strong> under consideration of publication elsewhere.</p><ul><li>I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.</li><li>I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).</li><li>I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.</li><li> I/We also agree to the authorship of the article in the following order:</li></ul><p>Author’s name </p><p> </p><p>1. ________________</p><p>2. ________________</p><p>3. ________________</p><p>4. ________________</p><table width="100%" border="0" cellpadding="0"><tbody><tr><td valign="top" width="5%"><p align="center"> </p></td><td valign="top" width="95%"><p>We Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.</p></td></tr></tbody></table>Formulation And Evaluation Of Itraconazole Loaded Solid Lipid Nanoparticles For Tinea Cruris:A Promising Approach To Combat Antifungal Drug Resistance
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP/article/view/1377
A fungal infection of the skin is among the most prevalent dermatological conditions worldwide. When used topically, gel formulations are among the best dose forms for treating skin infections. A promising method to reach the deeper layers of the skin and improve itraconazole (ITZ) permeability through the stratum corneum is nanotechnology. The production of ITZ-loaded nanoparticles (ITZ NPs) was accomplished through the evaporation emulsion method, and subsequently, these nanoparticles were integrated into a gel utilizing Carbopol 934 as the gelling agent. ITZ NP gel's physical characteristics, in vitro release, ex vivo penetration tests, and antifungal activity were all described. ITZ NPs had colloidal diameters between 200 nm and exhibited a nearly spherical form. The effectiveness of drug encapsulation was 98:79 ± 1:24%. Compared to a gel containing an ITZ-saturated suspension, ITZ NP gel showed a longer ex vivo penetration of ITZ over a 24-hour period via excised rat skin and a greater drug-penetrating capacity. The ITZ-loaded NP integrated gel exhibited superior in vitro antifungal activity compared to the ITZ dispersion. Through transdermal drug administration, the ITZ-loaded nanosystem integrated into gel may improve antifungal activity.Hamsa Priya MChandana MBharath BDarshan GSri lekha MDr. N. Venkatesan
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production
2024-01-292024-01-29103222810.37591/rrjodfdp.v10i3.1377Development and Assessment of A Herbal Hair Nourishment Oil Formulation
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP/article/view/1374
<p>This study focused on the formulation of herbal-based hair oils, recognizing hair as a vital component of the body and an essential protective appendage. In conjunction with sebaceous glands, sweat glands, and nails, hair is considered an accessory structure of the integumentary system. The widespread use of hair oils within the cosmetic industry by consumers prompted the formulation of these herbal-based products. The hair oil samples meticulously met specified standards for Color, Odor, PH, Viscosity, Density, Acid value, and Saponification value, aligning with the quality requirements of cosmetic products. The primary objective of this investigation was to standardize the chosen herbal-based hair oil, ensuring its conformity to specific physicochemical parameters and established standards. The formulation process, utilizing the boiling method for oil preparation, yielded outstanding results. This technique contributed to the overall success of the herbal-based hair oil, demonstrating excellence in meeting physicochemical criteria. The findings of this study not only validate the efficacy of the formulated product but also emphasize its potential as a standardized herbal-based solution in the cosmetic industry, meeting the discerning demands of consumers.</p>Mane Yogita LUbale Amol TMane Snehal S.Jadhav Shewata RPawar Neha VShinde Asha S
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production
2024-01-252024-01-251033951Risperidone: A Silver Lining In Mental Disorders
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP/article/view/1375
<p>Risperidone (RYKINDO®) is second generation benzisothiazole which elevates linkage to serotonin type 2 (5HT2A) and dopamine type 2(D2) receptor developed by Luye Pharma Group used in short term palliative treatment of aggression or psychopathic disorders. Both 5HT2 antagonism with D2 receptor, it selectively bind to 5HT2A antagonist and shows neuroleptic effect by Risperidone. It is also available in the form of oral solution and disintegrating tablet etc. It is long acting injectable formulation approved atypical antipsychotic risperidone and used for treatment of schizophrenia and bipolar disorder in adult.On 15 January 2023, FDA accepted Risperidone for treatment of schizophrenia in grown up, and as mono treatment and augmentation therapy to lethane and valproic acid sodium salt for treatment of schizophrenia and bipolar disorder, it is an atypical antipsychotic drug injected one time every twice week. The U.S. FDA has approved Risperidone for extended release injectable suspension. Phase III development is underway worldwide. This article summarize different aspects of Risperidone as API used to improve mental health. For instance, it has been the subject of open clinical trials for the treatment of bipolar disorder, schizophrenia in youth, and as a monotherapy or adjunctive treatment to Lithane or Valproic acid sodium salt for the continuation of manic depression therapy. It is also used as an antipsychotic medication for the treatment of juvenile mental disorders, in children with neurodevelopmental disorders, and in children with attention deficit or hyperkinetic syndrome behavior disturbances. In another trial, risperidone was tested in 101 children with autism disorder; in this instance, risperidone improved irritability and autism-related behavioral disorders.</p>Nikita GuravDhanshree PatilShweta PatilSayali Nejkar
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production
2024-01-252024-01-25103112110.37591/rrjodfdp.v10i3.1375Evaluating Ma-ul-Shae’er (Barley Water) as a Nutritional Supplement in Pulmonary Tuberculosis: A Randomised Controlled Trial
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP/article/view/1376
<p>Background: Tuberculosis (TB) stands as a persistent global health challenge, imposing significant burdens on societies across the world. Despite its profound medical, social, and economic implications, there exists a critical gap in understanding interventions that could improve the quality of life for individuals afflicted by TB.Objective: This study aims to fill this void by investigating the impact of barley water on the quality of life of TB patients, providing a unique perspective on a potential dietary intervention. The absence of prior research in this domain underscores the pioneering nature of this study.Methods: The research explores the historical context, drawing on Ma-ul-Shae’er (barley water) as documented in classical books of the Unani System of Medicine. The study evaluates the outcomes of incorporating barley water into the diet of TB patients, focusing on various parameters related to their well-being.Results: Promising outcomes were observed, suggesting significant improvements in the quality of life of TB patients. Notably, Ma-ul-Shae’er emerged as a favourable dietary medicine, as endorsed by classical texts in the Unani System of Medicine.Conclusion: These findings highlight a novel avenue for enhancing the well-being of TB patients, emphasizing the urgency of addressing the enduring challenges posed by TB. The study underscores the need for comprehensive investigations to precisely determine the efficacy of barley water in improving the quality of life among individuals afflicted by tuberculosis.</p>Atiya AnjumSalahuddin .Rubi AnjumKhalid Umer KhayyamSumeera Bandey
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production
2024-01-252024-01-25103293810.37591/rrjodfdp.v10i3.1376A comprehensive study on interactions between protein molecules and their importance in Drug Discovery
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP/article/view/1358
Protein-protein interactions (PPIs) are extremely specialized chemical and physical interactions that occur when two or more protein molecules come into contact with one another with the help of biochemical processes impacted by interactions between them, such as hydrogen bonding, electrostatic forces, and the hydrogen effect. Many interactions that occur in a specific bimolecular environment within a cell or living creature entail physical contact as well as molecular connections between chains. Protein-protein interactions have a major impact on both the target protein's function and a molecule's capacity to bind into the targeted sites that show beneficial effects. The majority of proteins and genes understand that the final phenotype is a result of several interactions. PPIs include signal transmission, muscle contraction, membrane transport including active and passive transport, cell metabolism, and electron transport proteins. The understanding of protein interaction networks is extremely beneficial to the study of the signal transduction pathway. The majority of proteins and genes regard the actions that result in the phenotype as a group of interplays. There are some methods to carry out the procedure which will include affinity purification, yeast 2 hybrid, tandem affinity purification, and other in vitro and in vivo methods, such as costs, times, and other variables. When it comes to annotating the function of pharmacological molecules, the resulting data sets are also noisy and have a larger proportion of false positives. As a result, in silico methods including chromosome proximity, gene fusion, sequence-based, and structure-based approaches were created. This study will help to know more about PPIs and the database that is available to carry out the further interactions that ia happened in the protein molecules and also helpfull to minimizing them.Pankaj MalhotraTaneesha Gupta
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production
2023-12-122023-12-1210311010.37591/rrjodfdp.v10i3.1358Review on Drug induced hematological disorder.
https://pharmajournals.stmjournals.in/index.php/RRJoDFDP/article/view/1344
Drugs have the potential to profoundly impact not just the bone marrow, but also the entire spectrum of peripheral blood cells, leading to a wide array of hematologic disorders. These pharmaceutical-induced conditions can affect white blood cells, red blood cells, platelets, and the coagulation system, posing a significant risk in modern pharmacotherapy. Among the drug-induced syndromes, some noteworthy examples include aplastic anemia, agranulocytosis, hemolytic anemia, megaloblastic anemia, thrombocytopenia, methemoglobinemia, sideroblastic anemia, and pure blood cell aplasia. These drug-related hematologic complications underscore the importance of careful monitoring and vigilant management when prescribing and using medications, as they can potentially be life-threatening.Roshan B. BadheSamiksha Amrutkar
Copyright (c) 2023 Research & Reviews: A Journal of Drug Formulation, Development and Production
2023-11-162023-11-16103182210.37591/rrjodfdp.v10i2.1344